Clinical Scorecard: First treatment for GD3 neurological symptoms approved
At a Glance
| Category | Detail |
|---|---|
| Condition | Clinical topic addressed by the source article: First Gaucher type 3 neurological drug approved |
| Key Mechanisms | Mechanisms or clinical associations described in the source article. |
| Target Population | Patients or participants described in the source article. |
| Care Setting | FDA-approved for adults and pediatric patients with GD3 weighing at least 15 kg. The supporting trial enrolled patients with stable systemic disease after prior enzyme replacement therapy. |
Key Highlights
- The FDA approved venglustat (Infilbray) as the first treatment authorized for neurological symptoms of GD3.
- Approval applies to adults and pediatric patients weighing at least 15 kg.
- In a 52-week trial, venglustat improved a combined neurological assessment compared with enzyme replacement therapy used for nonneurological manifestations.
- The trial enrolled 43 patients aged 12 years and older who had previously received enzyme replacement therapy and achieved stable systemic disease.
- Commonly reported adverse effects included gastrointestinal symptoms and mood-related changes; serious psychiatric risks included suicidal ideation and behavior.
Guideline-Based Recommendations
Diagnosis
Management
- FDA-approved for adults and pediatric patients with GD3 weighing at least 15 kg.
- In the 52-week trial, venglustat was taken orally once daily; the comparator was intravenous enzyme replacement therapy every 2 weeks.
Monitoring & Follow-up
- Frequently reported adverse effects included gastrointestinal symptoms and mood-related changes.
- Serious psychiatric risks, including suicidal ideation and behavior, were reported.
Risks
- Animal studies identified potential visual clouding risks in younger patients.
- Animal studies identified adverse effects on fetal development when the drug is taken during pregnancy.
Patient & Prescribing Data
FDA-approved for adults and pediatric patients with GD3 weighing at least 15 kg. The supporting trial included patients aged 12 years and older with stable systemic disease after prior enzyme replacement therapy.
Venglustat is taken orally once daily and was studied for 52 weeks. The FDA announcement did not provide numerical estimates of treatment effects.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
